Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132:1998–2004. https://doi.org/10.1038/jid.2012.35.

Article  CAS  PubMed  Google Scholar 

Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479–85. https://doi.org/10.1016/j.jaad.2011.06.032.

Article  PubMed  Google Scholar 

Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320–32. https://doi.org/10.1016/S0140-6736(12)61140-4.

Article  PubMed  Google Scholar 

Borradori L, Murrell DF, Hall RP. Bullous pemphigoid (cutaneous pemphigoid): the spectrum of clinical presentations. In: Murrell DF, editor. Blistering diseases: clinical features, pathogenesis, treatment. Heidelberg: Springer-Verlag, Berlin Heidelberg; 2015. p. 335–42. https://doi.org/10.1007/978-3-662-45698-9_31.

Chapter  Google Scholar 

Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91:601–3. https://doi.org/10.1590/abd1806-4841.20164935.

Article  PubMed  PubMed Central  Google Scholar 

Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99:243–50. https://doi.org/10.1111/1523-1747.ep12616580.

Article  CAS  PubMed  Google Scholar 

Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002;119:1065–73. https://doi.org/10.1046/j.1523-1747.2002.19529.x.

Article  CAS  PubMed  Google Scholar 

Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14:1115083. https://doi.org/10.3389/fimmu.2023.1115083.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seidman JS, Eichenfield DZ, Orme CM. Targeting type 2 inflammation for treatment of bullous pemphigoid. J Dermatol Skin Sci. 2020;2:29–33.

Google Scholar 

Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol. 2001;117:1097–102. https://doi.org/10.1046/j.0022-202x.2001.01505.x.

Article  CAS  PubMed  Google Scholar 

Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18:513–28. https://doi.org/10.1007/s40257-017-0264-2.

Article  PubMed  Google Scholar 

Shenoy P, Harugeri A. Elderly patients’ participation in clinical trials. Perspect Clin Res. 2015;6:184–9. https://doi.org/10.4103/2229-3485.167099.

Article  PubMed  PubMed Central  Google Scholar 

Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506. https://doi.org/10.3389/fimmu.2019.01506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Diaz LA, Giudice GJ. Autoimmune response against the bullous pemphigoid 180 autoantigen. Dermatology. 1994;189(Suppl. 1):34–7. https://doi.org/10.1159/000246925.

Article  PubMed  Google Scholar 

Schmidt E, Obe K, Bröcker E-B, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8. https://doi.org/10.1001/archderm.136.2.174.

Article  CAS  PubMed  Google Scholar 

Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci. 2018;1413:92–103. https://doi.org/10.1111/nyas.13561.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dainichi T, Chow Z, Kabashima K. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid. J Dermatol Sci. 2017;88:265–70. https://doi.org/10.1016/j.jdermsci.2017.07.012.

Article  CAS  PubMed  Google Scholar 

Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol. 2005;125:467–72. https://doi.org/10.1111/j.0022-202X.2005.23853.x.

Article  CAS  PubMed  Google Scholar 

Fairley JA, Burnett CT, Fu C-L, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol. 2007;127:2605–11. https://doi.org/10.1038/sj.jid.5700958.

Article  CAS  PubMed  Google Scholar 

Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol. 2003;120:784–8. https://doi.org/10.1046/j.1523-1747.2003.12146.x.

Article  CAS  PubMed  Google Scholar 

Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49:153–61. https://doi.org/10.1016/j.jdermsci.2007.08.008.

Article  CAS  PubMed  Google Scholar 

Kalowska M, Ciepiela O, Kowalewski C, Demkow U, Schwartz RA, Wozniak K. Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Derm Venereol. 2016;96:191–6. https://doi.org/10.2340/00015555-2101.

Article  CAS  PubMed  Google Scholar 

Freire PC, Muñoz CH, Stingl G. IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. Br J Dermatol. 2017;177:1644–53. https://doi.org/10.1111/bjd.15924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33:67–77. https://doi.org/10.1007/s12016-007-0030-y.

Article  CAS  PubMed  Google Scholar 

Fang H, Zhang Y, Li N, Wang G, Liu Z. The autoimmune skin disease bullous pemphigoid: the role of mast cells in autoantibody-induced tissue injury. Front Immunol. 2018;9:407. https://doi.org/10.3389/fimmu.2018.00407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wintroub BU, Mihm MC Jr, Goetzl EJ, Soter NA, Austen KF. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med. 1978;298:417–21. https://doi.org/10.1056/NEJM197802232980803.

Article  CAS  PubMed  Google Scholar 

Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001;108:1151–8. https://doi.org/10.1172/JCI11494.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keller Rosenthal N, Boucher D, Murrell DF. The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: a retrospective study. Front Med (Lausanne). 2022;9:1051804. https://doi.org/10.3389/fmed.2022.1051804.

Article  PubMed  Google Scholar 

Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. 1997;100:1256–63. https://doi.org/10.1172/JCI119639.